Wang Zhinong | Doctor/Chief Scientist
1994.4-1999.7 Osaka University Medical School
Doctor of Medicine, Ph.D. Medical Science
Major: Molecular Physiological Biochemistry
1999.10-2002.09 Postdoctoral Researcher
Research Direction:The molecular mechanism of the regulation of Steroidogenesis in adrenal
Endocrinology Laboratory, University of Texas Southwestern Medical Center (Dallas
Is the world's first to discover:
The cloned salt-induced protein kinase (SIK1) gene, hepatic nuclear receptor-1 (LRH-1) gene, and cholesterol 24-position reductase (DHCR24/Seladin-1) gene are important genes for the occurrence and development of major diseases such as tumors, hypertension, diabetes, cardiomyopathy, Alzheimer's disease, reproductive medicine, and aging, as well as target genes for drug research and development. Develop molecular biology diagnostic reagents, drugs targeting tumor metastasis, and drugs for Alzheimer's disease (AD) targeting the salt-induced protein kinase (SIK1) gene, hepatic nuclear receptor-1 (LRH-1) gene, and cholesterol 24-position reductase (DHCR24/Seladin-1) gene
A major discovery paper of the SIK1 gene published in Japan
Zhang Shiran | Chief R&D Engineer
2001.9- 2005.7 Undergraduate, Xi 'an Jiaotong University, Electronic Science and Technology
2006.9- 2008.7 Master's Degree, Information and Computing Science, Zhejiang University
2008.10- 2013.5 R&D Engineer, Medtronic (Shanghai) Research Institute
2013.6-2024.12: Director of R&D, Johnson & Johnson (Shanghai) Medical Devices Co., LTD
Fu Jiewei | Director/Vice President
Mr. Fu Jiewei has a profound background in the medical industry and outstanding strategic management capabilities. His academic and professional resume combines an international perspective with local practice.
Doctor of Medicine (MD-PhD Joint Training Program) from the School of Medicine, Tsinghua University, with a research direction of [Precision Medicine/Biomedical Engineering]. During this period, several high-impact SCI papers were published.
Visiting scholar at the School of Public Health, Johns Hopkins University, USA, focusing on medical policies and hospital management, participated in three WHO cooperation projects.
Judy | Director/Vice President
Ms. Judy is the manager of a quantum investment fund, with a globally outstanding academic background and over 15 years of financial investment experience. She focuses on private equity (PE), venture capital (VC), and cross-border mergers and acquisitions, and has led the successful exits of multiple billion-scale projects.
Bachelor of Economics (Summa Cum Laude with honors) from the Wharton School of the University of Pennsylvania, majoring in finance and mining in Computer Science (Quantitative Investment direction).
Zhu Jiachao | Director
Mr. Zhu Jiachao has been deeply involved in the medical device industry for 16 years, focusing on the market development and channel strategy of medical equipment and high-value consumables. He has extensive experience from front-line sales to senior management and has successfully driven many enterprises to achieve a doubling of their performance.
Bachelor of Biomedical Engineering (Medical Device Direction), School of Medicine, Sun Yat-sen University, systematically studying the research and development and clinical application of medical equipment.
The EMBA (Healthcare Industry Class) of Antai College of Economics and Management, Shanghai Jiao Tong University, focuses on the strategy and marketing management of medical enterprises.
Chi Xiaowei | Director /CFO
Ms. Chi Xiaowei has 10 years of experience in financial management and capital operation, specializing in corporate financial strategy, investment and financing management, and IPO preparation. She possesses the full-cycle financial management capabilities from start-ups to mature enterprises.
Master of Accounting (Financial Management Direction) from Southwestern University of Finance and Economics
Bachelor of Financial Management from Zhongnan University of Economics and Law
Certified Public Accountant (CPA) of the Ministry of Finance
